My study uses an Aβ1-42-induced Alzheimer’s disease rat model, and I plan to administer both Aducanumab and Lecanemab as positive controls. However, I am unsure about the optimal dosing regimen (e.g., dose, frequency, route of administration). Has anyone conducted similar experiments and could provide guidance? Any advice would be greatly appreciated!
Hi，Chloe，
Current literature reports indicate that Aducanumab has been studied in mouse models, but no relevant reports have been found regarding rat models. Research data on Lecanemab primarily originate from clinical trials, with no published studies identified in either mouse or rat models. Given the significant variations in dosing parameters (including dose level, administration route, and frequency) across different animal models, it is recommended to conduct pilot experiments prior to formal studies. This should involve establishing high- and low-dose groups with concentration gradient optimization to determine optimal experimental conditions.
https://www.foundersc.com/u/cms/www/ZX/20231019/a6c0b3c35f384d04ac99e03a6a1ff109.pdf。
The answer to this question comes from MedChemExpress (MCE) Technical Support.
- Badges
- Science topic
- Similar topics
- Chemistry
- Pharmacology
- Pharmaceuticals
- Drugs